Drug Trial Radar · NCT00144339
Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients
Last checked: Nov 20, 2026Latest source record: May 20, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5,993
Actual
Start
Dec 2002
Primary completion
Feb 2008
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Sep 5, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Model
- Parallel
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this trial is to determine whether daily treatment with tiotropium (Spiriva®, Bromuro de Tiotropio®) inhalation capsule via HandiHaler® reduces the rate of decline in lung function over time in patients with COPD.
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
tiotropiumDrug
placeboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 YearsTime frame: From day 30 to 4 years
- Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 YearsTime frame: From day 30 to 4 years
Locations
490 sites in 37 countries. Site status is shown where the registry gives one.
205.235.3779 Boehringer Ingelheim Investigational Site
Anniston, Alabama
205.235.3785 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
205.235.3804 Boehringer Ingelheim Investigational Site
Jasper, Alabama
205.235.3795 Boehringer Ingelheim Investigational Site
Mobile, Alabama
205.235.3759 Boehringer Ingelheim Investigational Site
Phoenix, Arizona
205.235.3770 Boehringer Ingelheim Investigational Site
Carmichael, California
205.235.3778 Boehringer Ingelheim Investigational Site
Escondito, California
205.235.3810 Boehringer Ingelheim Investigational Site
Lakewood, California
205.235.3758 Boehringer Ingelheim Investigational Site
Long Beach, California
205.235.3812 Boehringer Ingelheim Investigational Site
Long Beach, California
205.235.3773 Boehringer Ingelheim Investigational Site
Los Angeles, California
205.235.3800 Boehringer Ingelheim Investigational Site
Los Angeles, California
205.235.3802 Boehringer Ingelheim Investigational Site
Los Angeles, California
205.235.3786 Pulmonary and Critical Care Medicine
Orange, California
205.235.3811 Boehringer Ingelheim Investigational Site
Palo Alto, California
205.235.3741 Boehringer Ingelheim Investigational Site
Rancho Mirage, California
205.235.3717 Boehringer Ingelheim Investigational Site
San Diego, California
205.235.3781 Boehringer Ingelheim Investigational Site
San Diego, California
205.235.3784 Boehringer Ingelheim Investigational Site
San Diego, California
205.235.3760 Boehringer Ingelheim Investigational Site
Sepulveda, California
205.235.3711 Boehringer Ingelheim Investigational Site
Stockton, California
205.235.3764 Boehringer Ingelheim Investigational Site
Denver, Colorado
205.235.3783 Boehringer Ingelheim Investigational Site
Wheat Ridge, Colorado
205.235.3727 Boehringer Ingelheim Investigational Site
Hartford, Connecticut
205.235.3808 Boehringer Ingelheim Investigational Site
Hartford, Connecticut
205.235.3793 Boehringer Ingelheim Investigational Site
Norwalk, Connecticut
205.235.3815 Boehringer Ingelheim Investigational Site
West Haven, Connecticut
205.235.3706 Boehringer Ingelheim Investigational Site
Bay Pines, Florida
205.235.3762 Boehringer Ingelheim Investigational Site
Brandon, Florida
205.235.3707 Boehringer Ingelheim Investigational Site
Largo, Florida
205.235.3703 Boehringer Ingelheim Investigational Site
Melbourne, Florida
205.235.3775 Boehringer Ingelheim Investigational Site
Panama City, Florida
205.235.3743 Boehringer Ingelheim Investigational Site
Sarasota, Florida
205.235.3756 Boehringer Ingelheim Investigational Site
Tampa, Florida
205.235.3739 Boehringer Ingelheim Investigational Site
West Palm Beach, Florida
205.235.3719 Boehringer Ingelheim Investigational Site
Atlanta, Georgia
205.235.3790 Boehringer Ingelheim Investigational Site
Atlanta, Georgia
205.235.3716 Boehringer Ingelheim Investigational Site
Augusta, Georgia
205.235.3794 Boehringer Ingelheim Investigational Site
Stockbridge, Georgia
205.235.3724 Boehringer Ingelheim Investigational Site
Coeur d'Alene, Idaho
Showing 40 of 490 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.